Brodalumab

Creative Commons License

Borlu M.

TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY, cilt.56, ss.58-60, 2022 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 56
  • Basım Tarihi: 2022
  • Doi Numarası: 10.4274/turkderm.galenos.2022.01643
  • Dergi Adı: TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.58-60
  • Anahtar Kelimeler: Anti-IL-17RA, brodalumab, psoriasis, PSORIASIS, PHARMACOKINETICS, EFFICACY, SINGLE, SAFETY
  • Erciyes Üniversitesi Adresli: Evet

Özet

Brodalumab is a human monoclonal antibody that inhibits interleukin-17 (IL-17) pathway by binding to IL-17 receptor. In clinical trials, a PASI75 response has been achieved in 82-84% of the patients at week 12. It was shown to be effective also in generalized pustular and erythrodermic psoriasis. As with other IL-17 inhibitors, brodalumab should be used with caution in patients with inflammatory bowel disease.